NCT05653323View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Pain
Interventions
DRUG

VX-993

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (1)

Unknown

MAC Clinical Research, Manchester

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY